Nektar Selling 19M Shares as Firm Goes Solo on NKTR-102

A week after President and CEO Howard W. Robin told investors at the J.P. Morgan Healthcare Conference in San Francisco that Nektar Therapeutics Inc. planned to move into Phase III on its own with cancer drug NKTR-102, the firm priced a hefty public offering to bolster its cash reserves.